Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes

Biomedicine and Pharmacotherapy

Volumn 89, Issue , 2017, Pages 1242-1251

  Asrafuzzaman, Md ^a   Cao, Yingnan ^b   Afroz, Rizwana ^c   Kamato, Danielle ^c   Gray, Susan ^c   Little, Peter J ^b,c  

^a BANGLADESH UNIVERSITY OF HEALTH SCIENCES   (Bangladesh)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Animal models; Genetics; Hyperglycaemia; Streptozotocin

Indexed keywords

ALLOXAN; AUROTHIOGLUCOSE; NATURAL PRODUCT; NICOTINAMIDE; STREPTOZOCIN; ANTIDIABETIC AGENT; BIOLOGICAL PRODUCT;

ANIMAL EXPERIMENT; ANIMAL MODEL; EXPERIMENTAL MODEL; GENETIC MODEL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PATHOPHYSIOLOGY; PIG; PRIORITY JOURNAL; RAT; REVIEW; RHESUS MONKEY; WESTERN MEDICINE; ANIMAL; HUMAN; PHYSIOLOGY;

ANIMALS; BIOLOGICAL PRODUCTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MODELS, ANIMAL;

EID: 85015388048     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.03.010     Document Type: Review

References (109)

1. [1] Guariguata, L., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103:2 (2014), 137–149.
2. [2] Ong, C.R., et al. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 29:11 (2006), 2361–2364.
3. [3] Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15:7 (1998), 539–553.
4. [4] American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care(27 Suppl. 1), 2004, S5–S10.
5. [5] Dunstan, D.W., et al. A randomised: controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. Thromb. Haemost. 81:3 (1999), 367–372.
6. [6] Dunstan, D.W., et al. Association of television viewing with fasting and 2-h postchallenge plasma glucose levels in adults without diagnosed diabetes. Diabetes Care 30:3 (2007), 516–522.
7. [7] Cooper, M.E., et al. Mechanisms of diabetic vasculopathy: an overview. Am. J. Hypertens. 14:5 Pt. 1 (2001), 475–486.
8. [8] Cooper, M.E., Gilbert, R.E., Epstein, M., Pathophysiology of diabetic nephropathy. Metabolism 47:12 Suppl. 1 (1998), 3–6.
9. [9] Nigro, J., et al. Insulin resistance and atherosclerosis. Endocr. Rev. 27:3 (2006), 242–259.
10. [10] Little, P.J., Osman, N., O'Brien, K.D., Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr. Opin. Lipidol. 19 (2008), 448–454.
11. [11] Little, P.J., Chait, A., Bobik, A., Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol. Ther. 131:3 (2011), 255–268.
12. [12] Libby, P., Inflammation in atherosclerosis. Nature 420:6917 (2002), 868–874.
13. [13] Haffner, S.J., Cassells, H., Hyperglycemia as a cardiovascular risk factor. Am. J. Med. 115:Suppl. 8A (2003), 6S–11S.
14. [14] de Dios, S.T., et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery: radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107:20 (2003), 2548–2550.
15. [15] de Dios, S.T., et al. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J. Diabetes Complications 21:2 (2007), 108–117.
16. [16] de Dios, S.T., et al. Troglitazone: but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J. Diabetes Complications 15:3 (2001), 120–127.
17. [17] Little, P.J., Cemerlang, N., Osman, N., Thiazolidinediones are more potent inhibitors of vascular smooth muscle cell proliferation under high glucose conditions. 66th Annual Meeting American Diabetes Association, Washington D.C.: Diabetes, 2006.
18. [18] Haffner, S.M., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:4 (1998), 229–234.
19. [19] Reaven, G.M., Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 37:12 (1988), 1595–1607.
20. [20] Reaven, G.M., HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?. Diab. Vasc. Dis. Res. 6:2 (2009), 133–138.
21. [21] Mudaliar, S., Henry, R.R., The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 55:7 (2012), 1865–1868.
22. [22] Little, P.J., Osman, N., Cohen, N., Understanding diabetes and its complications for biomedical research. Int. J. Diabetol. Vasc. Dis. Res. 1:4 (2013), 401–404.
23. [23] Cao, Y., Kamato, D., Little, P.J., Animal models for the evaluation of the cardiometabolic therapeutic potential of Traditional Chinese and Natural Product Medicinces. Int. J. Diabetol. Vasc. Dis. Res., 2017.
24. [24] Hollenbeck, C., Reaven, G.M., Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J. Clin. Endocrinol. Metab. 64:6 (1987), 1169–1173.
25. [25] Bansilal, S., Farkouh, M.E., Fuster, V., Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am. J. Cardiol. 99:4A (2007), 6B–14B.
26. [26] Chatzigeorgiou, A., et al. The use of animal models in the study of diabetes mellitus. In Vivo 23:2 (2009), 245–258.
27. [27] King, A.J., The use of animal models in diabetes research. Br. J. Pharmacol. 166:3 (2012), 877–894.
28. [28] Srinivasan, K., Ramarao, P., Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 125:3 (2007), 451–472.
29. [29] Sakata, N., et al. Animal models of diabetes mellitus for islet transplantation. Exp. Diabetes Res., 2012, 2012, 256707.
30. [30] Silva, A., Andersen, M.L., Tufik, S., Sleep pattern in an experimental model of osteoarthritis. Pain 140:3 (2008), 446–455.
31. [31] Ingalls, A.M., Dickie, M.M., Snell, G.D., Obese, a new mutation in the house mouse. J. Hered. 41:12 (1950), 317–318.
32. [32] Falconer, D.S., Isaacson, J.H., Adipose, A new inherited obesity of the mouse. J. Hered. 50:6 (1959), 290–292.
33. [33] Wong, S.K., et al. Animal models of metabolic syndrome: a review. Nutr. Metab. (Lond.), 13, 2016, 65.
34. [34] Nakamura, M., A diabetic strain of the mouse. Proce. Japan Acad. 38 (1962), 348–352.
35. [35] Bielschowsky, M., Goodall, C.M., Origin of inbred NZ mouse strains. Cancer Res. 30:3 (1970), 834–836.
36. [36] Subrahmanyam, K., Metabolism in the New Zealand strain of obese mice. Biochem. J. 76:3 (1960), 548–556.
37. [37] Sims, E.A., et al. Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29 (1973), 457–496.
38. [38] Alberti, K.G., Zimmet, P.Z., Diabetes: a look to the future. Lancet Diabetes Endocrinol. 2:1 (2014), pe1–2.
39. [39] Zimmet, P.Z., et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2:1 (2014), 56–64.
40. [40] Suzuki, W., et al. A new mouse model of spontaneous diabetes derived from ddY strain. Exp. Anim. 48:3 (1999), 181–189.
41. [41] Iizuka, S., et al. Diabetic complications in a new animal model (TSOD mouse) of spontaneous NIDDM with obesity. Exp. Anim. 54:1 (2005), 71–83.
42. [42] Allan, M.F., Eisen, E.J., Pomp, D., The M16 mouse: an outbred animal model of early onset polygenic obesity and diabesity. Obes. Res. 12:9 (2004), 1397–1407.
43. [43] Wilmot, E., Idris, I., Early onset type 2 diabetes: risk factors, clinical impact and management. Ther. Adv. Chronic Dis. 5:6 (2014), 234–244.
44. [44] Zucker, L.M., Zucker, T.F., Fatty, A new mutation in the rat. J. Hered. 52:6 (1961), 275–278.
45. [45] Michaelis, O.E., Hansen, C.T., The spontaneous hypertensive/NIH-corpulent rat: a new rodent model for the study of non-insulin-dependent diabetes mellitus and its complications. ILAR J. 32:3 (1990), 19–22.
46. [46] Kawano, K., et al. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:11 (1992), 1422–1428.
47. [47] Cohen, A.M., Rosenmann, E., Rosenthal, T., The Cohen diabetic (non-insulin-dependent) hypertensive rat model: description of the model and pathologic findings. Am. J. Hypertens. 6:12 (1993), 989–995.
48. [48] Gauguier, D., et al. Chromosomal mapping of genetic loci associated with non-insulin dependent diabetes in the GK rat. Nat. Genet. 12:1 (1996), 38–43.
49. [49] Shinohara, M., et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int. J. Exp. Diabetes Res. 1:2 (2000), 89–100.
50. [50] Kim, J.H., et al. Type 2 diabetes mouse model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obesity. Physiol. Genomics 22:2 (2005), 171–181.
51. [51] Lozano, I., et al. High-fructose and high-fat diet-induced disorders in rats: impact on diabetes risk, hepatic and vascular complications. Nutr. Metab. (Lond.), 13, 2016, 15.
52. [52] Swinburn, B.A., et al. Diet, nutrition and the prevention of excess weight gain and obesity. Public Health Nutr. 7:1A (2004), 123–146.
53. [53] Lorenzo, C., et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:11 (2003), 3153–3159.
54. [54] Deurenberg, P., Deurenberg-Yap, M., Guricci, S., Obes. Rev. 3:3 (2002), 141–146.
55. [55] Banerji, M.A., et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J. Clin. Endocrinol. Metab. 84:1 (1999), 137–144.
56. [56] Yoshioka, M., et al. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46:5 (1997), 887–894.
57. [57] Winzell, M.S., Ahren, B., The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53:Suppl. 3 (2004), S215–S219.
58. [58] Winzell, M.S., et al. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem. Biophys. Res. Commun. 321:1 (2004), 154–160.
59. [59] Bardbosa-da-Silva, S., et al. Animal models of nutritional induction of type2 diabetes mellitus. Int. J. Morphol. 32:1 (2014), 279–293.
60. [60] Shibata, M., Yasuda, B., New experimental congenital diabetic mice (N.S.Y. mice). Tohoku J. Exp. Med. 130:2 (1980), 139–142.
61. [61] Rakieten, N., Rakieten, M.L., Nadkarni, M.V., Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother. Rep. 29 (1963), 91–98.
62. [62] Dhuria, R.S., et al. Current status and patent prospective of animal models in diabetic research. Adv. Biomed. Res., 4, 2015, 117.
63. [63] Arulmozhi, D.K., Veeranjaneyulu, A., Bodhankar, S.L., Neonatal streptozotocin-induced rat model of Type 2 diabetes mellitus: a glance. Indian J. Pharmacol. 36:4 (2004), 217–221.
64. [64] Palsamy, P., Subramanian, S., Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed. Pharmacother. 62:9 (2008), 598–605.
65. [65] Masiello, P., et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47:2 (1998), 224–229.
66. [66] Skovso, S., Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J. Diabetes Investig. 5:4 (2014), 349–358.
67. [67] Eleazu, C.O.et al., Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J. Diabetes Metab. Disord., 12(1), 2013, 60.
68. [68] Nugent, D.A., Smith, D.M., Jones, H.B., A review of islet of Langerhans degeneration in rodent models of type 2 diabetes. Toxicol. Pathol. 36:4 (2008), 529–551.
69. [69] Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50:6 (2001), 537–546.
70. [70] Karasawa, H., Takaishi, K., Kumagae, Y., Obesity-induced diabetes in mouse strains treated with gold thioglucose: a novel animal model for studying beta-cell dysfunction. Obesity (Silver Spring) 19:3 (2011), 514–521.
71. [71] Mishra, G., Panda, P.K., Satapathy, T., Animal models for type 2 diabetes: a review. World J. Pharm. Sci., 4(1), 2016.
72. [72] Ranjan, S., Sharma, P.K., Experimental model organisms in type 2 diabetes research: a review. Int. J. Adv. Res., 2015, 344–356.
73. [73] Kadowaki, T., Insights into insulin resistance and type 2 diabetes from knockout mouse models. J. Clin. Invest. 106:4 (2000), 459–465.
74. [74] Xi, S., et al. A minipig model of high-fat/high-sucrose diet-induced diabetes and atherosclerosis. Int. J. Exp. Pathol. 85:4 (2004), 223–231.
75. [75] Hotta, K., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:5 (2001), 1126–1133.
76. [76] Zinman, B., et al. Empagliflozin: cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373:22 (2015), 2117–2128.
77. [77] Marso, S.P., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2016.
78. [78] Zhang, Y., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372:6505 (1994), 425–432.
79. [79] Bahary, N., et al. Molecular mapping of the mouse db mutation. Proc. Natl. Acad. Sci. U. S. A. 87:21 (1990), 8642–8646.
80. [80] Bao, D., et al. Preliminary characterization of a leptin receptor knockout rat created by CRISPR/Cas9 system. Sci. Rep., 5, 2015, 15942.
81. [81] Li, J., et al. Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice. J. Tradit. Chin. Med. 32:3 (2012), 446–452.
82. [82] Yang, L., et al. Puerarin protects pancreatic beta-cells in obese diabetic mice via activation of GLP-1R signaling. Mol. Endocrinol. 30:3 (2016), 361–371.
83. [83] Manohar, V., et al. Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice. Diabetes Obes. Metab. 4:1 (2002), 43–48.
84. [84] Liu, Y., et al. Antidiabetic activity of polysaccharides from tuberous root of liriope spicata var: prolifera in KKAy mice. Evid. Based Complement. Alternat. Med., 2013, 2013, 349790.
85. [85] Miura, T., et al. Antidiabetic effect of Nitobegiku: the herb Tithonia diversifolia, in KK-Ay diabetic mice. Biol. Pharm. Bull. 28:11 (2005), 2152–2154.
86. [86] Akase, T., et al. Preventive effects of salacia reticulata on obesity and metabolic disorders in TSOD mice. Evid. Based Complement. Alternat. Med., 2011, 2011, 484590.
87. [87] Kim, J.H., et al. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J. Endocrinol. 191:2 (2006), 437–446.
88. [88] Mathews, C.E., Bagley, R., Leiter, E.H., ALS/Lt: a new type 2 diabetes mouse model associated with low free radical scavenging potential. Diabetes 53:Suppl. 1 (2004), S125–S129.
89. [89] Kurtz, T.W., Morris, R.C., Pershadsingh, H.A., The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13:6 Pt. 2 (1989), 896–901.
90. [90] Megalli, S., Davies, N.M., Roufogalis, B.D., Anti-hyperlipidemic and hypoglycemic effects of Gynostemma pentaphyllum in the Zucker fatty rat. J. Pharm. Pharm. Sci. 9:3 (2006), 281–291.
91. [91] Vance, J.E., Russell, J.C., Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J. Lipid Res. 31:8 (1990), 1491–1501.
92. [92] Wang, Z.Q., et al. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese: insulin-resistant JCR:LA-cp rats. J. Nutr. 136:2 (2006), 415–420.
93. [93] Lee, H.J., et al. Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats. Metabolism 58:8 (2009), 1170–1177.
94. [94] Ndong, M., et al. Effects of oral administration of moringa oleifera lam on glucose tolerance in Goto-Kakizaki and wistar rats. J. Clin. Biochem. Nutr. 40:3 (2007), 229–233.
95. [95] Surwit, R.S., et al. Control of expression of insulin resistance and hyperglycemia by different genetic factors in diabetic C57BL/6J mice. Diabetes 40:1 (1991), 82–87.
96. [96] Hayashi, Y., et al. Spontaneous development of organ-specific autoimmune lesions in aged C57BL/6 mice. Clin. Exp. Immunol. 78:1 (1989), 120–126.
97. [97] Jayaprakasam, B., et al. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J. Agric. Food Chem. 54:1 (2006), 243–248.
98. [98] Ueda, H., et al. Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of Type II diabetes mellitus; NSY mouse. Diabetologia 43:7 (2000), 932–938.
99. [99] Shafrir, E., Ziv, E., Cellular mechanism of nutritionally induced insulin resistance: the desert rodent Psammomys obesus and other animals in which insulin resistance leads to detrimental outcome. J. Basic Clin. Physiol. Pharmacol. 9:2–4 (1998), 347–385.
100. [100] Bennani-Kabchi, N., et al. Effect of Suaeda fruticosa aqueous extract in the hypercholesterolaemic and insulin-resistant sand rat. Therapie 54:6 (1999), 725–730.
101. [101] Joshi, R.L., et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J. 15:7 (1996), 1542–1547.
102. [102] Accili, D., et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12:1 (1996), 106–109.
103. [103] Bruning, J.C., et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88:4 (1997), 561–572.
104. [104] Bruning, J.C., et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2:5 (1998), 559–569.
105. [105] Kulkarni, R.N., et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:3 (1999), 329–339.
106. [106] Michael, M.D., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6:1 (2000), 87–97.
107. [107] Patti, M.E., et al. 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. J. Biol. Chem. 270:42 (1995), 24670–24673.
108. [108] Kubota, N., et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49:11 (2000), 1880–1889.
109. [109] Terauchi, Y., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 21:2 (1999), 230–235.